These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34642316)

  • 1. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.
    Prakadan SM; Alvarez-Breckenridge CA; Markson SC; Kim AE; Klein RH; Nayyar N; Navia AW; Kuter BM; Kolb KE; Bihun I; Mora JL; Bertalan MS; Shaw B; White M; Kaplan A; Stocking JH; Wadsworth MH; Lee EQ; Chukwueke U; Wang N; Subramanian M; Rotem D; Cahill DP; Adalsteinsson VA; Miller JW; Sullivan RJ; Carter SL; Brastianos PK; Shalek AK
    Nat Commun; 2021 Oct; 12(1):5955. PubMed ID: 34642316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
    Brastianos PK; Strickland MR; Lee EQ; Wang N; Cohen JV; Chukwueke U; Forst DA; Eichler A; Overmoyer B; Lin NU; Chen WY; Bardia A; Juric D; Dagogo-Jack I; White MD; Dietrich J; Nayyar N; Kim AE; Alvarez-Breckenridge C; Mahar M; Mora JL; Nahed BV; Jones PS; Shih HA; Gerstner ER; Giobbie-Hurder A; Carter SL; Oh K; Cahill DP; Sullivan RJ
    Nat Commun; 2021 Oct; 12(1):5954. PubMed ID: 34642329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
    Naik GS; Buchbinder EI; Cohen JV; Manos MP; Johnson AEW; Bowling P; Aizer AA; Schoenfeld JD; Lawrence DP; Haq R; Hodi FS; Sullivan RJ; Ott PA
    J Immunother; 2021 Oct; 44(8):307-318. PubMed ID: 34406158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review.
    Palmisciano P; Haider AS; Nwagwu CD; Wahood W; Yu K; Ene CI; O'Brien BJ; Aoun SG; Cohen-Gadol AA; El Ahmadieh TY
    Anticancer Res; 2021 Nov; 41(11):5333-5342. PubMed ID: 34732403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
    van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
    Front Immunol; 2021; 12():793964. PubMed ID: 34987518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
    Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
    Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
    Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
    Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
    Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in non-small cell lung cancer harbouring driver mutations.
    Addeo A; Passaro A; Malapelle U; Banna GL; Subbiah V; Friedlaender A
    Cancer Treat Rev; 2021 May; 96():102179. PubMed ID: 33798954
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
    Zhao J; Chen AX; Gartrell RD; Silverman AM; Aparicio L; Chu T; Bordbar D; Shan D; Samanamud J; Mahajan A; Filip I; Orenbuch R; Goetz M; Yamaguchi JT; Cloney M; Horbinski C; Lukas RV; Raizer J; Rae AI; Yuan J; Canoll P; Bruce JN; Saenger YM; Sims P; Iwamoto FM; Sonabend AM; Rabadan R
    Nat Med; 2019 Mar; 25(3):462-469. PubMed ID: 30742119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
    Berezhnoy A; Sumrow BJ; Stahl K; Shah K; Liu D; Li J; Hao SS; De Costa A; Kaul S; Bendell J; Cote GM; Luke JJ; Sanborn RE; Sharma MR; Chen F; Li H; Diedrich G; Bonvini E; Moore PA
    Cell Rep Med; 2020 Dec; 1(9):100163. PubMed ID: 33377134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab.
    Dietrich C; Salzmann M; Steinbrecher A; Herbst R; Hassel JC
    Immunotherapy; 2021 Sep; 13(13):1079-1083. PubMed ID: 34259028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decade of immune-checkpoint inhibitors in cancer therapy.
    Robert C
    Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
    Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
    Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.